Experimental Narcolepsy Drug Shows Positive Wakefulness Results for Alkermes
Summary
Alkermes announced positive trial results for an experimental drug, demonstrating improved wakefulness and reduced daytime sleepiness in patients with narcolepsy. This adds to a series of positive drug development news for the company, following positive Phase 3 results for LUMRYZ in narcolepsy in May and Orphan Drug Designations for alixorexton in June. Positive clinical data for a new drug candidate in a significant therapeutic area like narcolepsy can materially enhance the company's pipeline value and future revenue potential.
At the time of this announcement, ALKS was trading at $44.09 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.4B. The 52-week trading range was $25.17 to $45.76. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Binance News.